Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 20,500 Shares of Edwards Lifesciences Co. (NYSE:EW)

Fjarde AP Fonden Fourth Swedish National Pension Fund lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 15.5% during the 4th quarter, Holdings Channel reports. The firm owned 111,466 shares of the medical research company’s stock after selling 20,500 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Edwards Lifesciences were worth $8,252,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. International Assets Investment Management LLC increased its holdings in shares of Edwards Lifesciences by 10,990.6% in the third quarter. International Assets Investment Management LLC now owns 163,919 shares of the medical research company’s stock worth $10,817,000 after purchasing an additional 162,441 shares during the last quarter. Forsta AP Fonden increased its stake in Edwards Lifesciences by 12.0% in the 3rd quarter. Forsta AP Fonden now owns 134,000 shares of the medical research company’s stock worth $8,843,000 after acquiring an additional 14,400 shares during the last quarter. Smithbridge Asset Management Inc. DE raised its holdings in shares of Edwards Lifesciences by 20.2% during the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 13,086 shares of the medical research company’s stock worth $864,000 after acquiring an additional 2,202 shares in the last quarter. Forbes J M & Co. LLP boosted its position in shares of Edwards Lifesciences by 6.1% during the 3rd quarter. Forbes J M & Co. LLP now owns 5,610 shares of the medical research company’s stock valued at $370,000 after acquiring an additional 325 shares during the last quarter. Finally, abrdn plc grew its holdings in shares of Edwards Lifesciences by 1.7% in the third quarter. abrdn plc now owns 1,311,844 shares of the medical research company’s stock valued at $85,847,000 after purchasing an additional 22,271 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.8 %

Shares of NYSE:EW opened at $72.72 on Tuesday. The business’s 50 day moving average is $72.83 and its 200 day moving average is $70.13. The stock has a market cap of $42.89 billion, a P/E ratio of 10.43, a price-to-earnings-growth ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,489 shares of company stock valued at $2,002,829. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several research reports. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Citigroup lifted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.